Hepatocellular Carcinoma (HCC) is one of the most common malignancies, and its
incidence and mortality are increasing worldwide. Cancer immunotherapy has …

Hepatocellular carcinoma (HCC) is one of the most common malignant tumor in the world
and its incidence is increasing in many countries. In recent years, with the deepening …

Hepatocellular carcinoma (HCC) is the fifth most common cancer, and the second leading
cause of cancer-related death worldwide. Although recent advances in immune checkpoint …

The discovery of the immune checkpoint mechanism has contributed greatly to recent
advances in cancer treatment. The anticytotoxic T lymphocyte-associated protein 4 antibody …

A pharmacological class known as immune checkpoint inhibitors (ICIs) has been developed
as a potential treatment option for various malignancies, including HCC. In HCC, ICIs have …

Hepatocellular carcinoma (HCC) is the most common liver cancer with high morbidity and
mortality worldwide. Systemic treatments with several multi-targeted tyrosine kinase …

Hepatocellular carcinoma (HCC) is the most lethal and common type of liver cancer with
limited treatment options at the advanced stage. The use of immune checkpoint inhibitor …

Hepatocellular carcinoma (HCC) is one of the most common and fatal malignancies with an
alarming trend all around the world. Common therapeutic approaches in the early stage of …

In recent years, the incidence of liver cancer has increased and is currently the sixth most
common tumor and the second leading cause of cancer‑associated mortality worldwide …

The position of immunotherapy as a pillar of systemic cancer treatment has been firmly
established over the past decade. Immune checkpoint inhibitors are a welcome option for …